AntriaBio, Inc. Launches Digital Corporate Communication Channels

MENLO PARK, CA -- (Marketwired) -- 04/30/14 -- AntriaBio, Inc. (OTCQB: ANTB), a biopharmaceutical company focused on developing novel therapeutics to treat patients with diabetes and metabolic disease, announced today a suite of online corporate communication channels to maintain on-going direct communication with shareholders and other interested parties. The Company has launched official portals on social media channels including Facebook, Twitter, LinkedIn, Google+, YouTube and The Chairman's Blog.

The Chairman's Blog is an online communication portal where AntriaBio executives can address important topics as they relate to the diabetes market as well as specific points of discussion as they relate to key events at AntriaBio. Chairman and CEO, Nevan Elam, penned his inaugural blog post, "Introducing AntriaBio." The blog post can be found online at the official AntriaBio Chairman's Blog profile provided below.

Mr. Elam commented, "The launch of our digital communication channels is an important component of AntriaBio's communications strategy and awareness campaign utilizing social media channels. We believe this will allow us to communicate transparently and more frequently with our current shareholder base, and more broadly with the entire investing public, while maintaining compliance with all securities laws."

Links to the new communication tools are here:

Facebook: https://www.facebook.com/antriabio

Twitter: https://twitter.com/antriabio

LinkedIn: https://www.linkedin.com/company/antriabio-inc-/

Google+: https://plus.google.com/+AntriabioInc/posts

The Chairman's Blog Profile: http://www.thechairmansblog.com/antriabio/

About AntriaBio, Inc.
AntriaBio is a biopharmaceutical company focused on developing novel therapeutics to treat patients with diabetes and metabolic disease. AntriaBio's development strategy combines FDA approved pharmaceutical agents with its proprietary delivery technology. AntriaBio's lead product candidate is AB101, an injectable once-a-week basal insulin for Type 1 and Type 2 diabetes. For more information visit: www.antriabio.com.

About TheChairmansBlog.com
TheChairmansBlog.com is an exclusive, online media publication where publicly and privately held firms alike share insights about their companies and industries. TheChairmansBlog.com enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. www.thechairmansblog.com

Forward-Looking Statements
This release, like many written and oral communications presented by AntriaBio, Inc., and our authorized officers, may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of the Company, are generally identified by use of words "anticipate," "believe," "estimate," "expect," "intend," "plan," "project," "seek," "strive," "try," or future or conditional verbs such as "could," "may," "should," "will," "would," or similar expressions. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. Accordingly, actual results may differ materially from anticipated results. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Except as required by applicable law or regulation, AntriaBio undertakes no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made.

AntriaBio, Inc. Contact:
Jenene Thomas
Jenene Thomas Communications, LLC
(908) 938-1475
Email Contact

Source: AntriaBio Inc.

Released April 30, 2014